Home
HelpOrder Code CTX Beta-CrossLaps, Serum
Reporting Name
Beta-CrossLaps (B-CTx), SUseful For
Monitoring antiresorptive therapies (eg, bisphosphonates and hormone replacement therapy) in postmenopausal women treated for osteoporosis and individuals diagnosed with osteopenia
An adjunct in the diagnosis of medical conditions associated with increased bone turnover
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SerumSpecimen Required
Patient Preparation: Patient should fast for 12 hours before specimen collection.
Supplies: Sarstedt Aliquot Tube, 5 mL (T914)
Collection Container/Tube:
Preferred: Red top
Acceptable: Serum gel
Submission Container/Tube: Plastic vial
Specimen Volume: 1 mL
Collection Instructions:
1. Collect specimen prior to 10 a.m.
2. Centrifuge and aliquot serum into plastic vial.
Specimen Minimum Volume
0.75 mL
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Frozen (preferred) | 90 days | |
| Refrigerated | 72 hours |
Reference Values
Males
<5 years: 242-1292 pg/mL
5-9 years: 351-1532 pg/mL
10-15 years: 447-2457 pg/mL
16-17 years: 478-1666 pg/mL
18-29 years: 238-1019 pg/mL
30-39 years: 225-936 pg/mL
40-49 years: 182-801 pg/mL
50-59 years: 161-737 pg/mL
60-69 years: 132-752 pg/mL
≥70 years: 118-776 pg/mL
Females
<5 years: 347-1508 pg/mL
5-9 years: 383-1556 pg/mL
10-15 years: 311-1776 pg/mL
16-17 years: 146-1266 pg/mL
18-29 years: 148-967 pg/mL
30-39 years: 150-635 pg/mL
40-49 years: 131-670 pg/mL
50-59 years: 183-1060 pg/mL
60-69 years: 171-970 pg/mL
≥70 years: 152-858 pg/mL
Premenopausal: 136-689 pg/mL
Postmenopausal: 177-1015 pg/mL
Day(s) Performed
Monday through Saturday
CPT Code Information
82523
Method Description
The Roche Beta-CrossLaps/serum assay is a 2-site immunometric (sandwich) assay using electrochemiluminescence detection. Patient specimen, biotinylated monoclonal beta-CrossLaps-specific antibody, and monoclonal beta-CrossLaps-specific antibody labeled with ruthenium react to form a complex. Streptavidin-coated microparticles act as the solid phase to which the complex binds. Voltage is applied to the electrode, inducing a chemiluminescent emission from the ruthenium, which is then measured against a calibration curve to determine the amount of beta-CrossLaps in the patient specimen. This assay is specific for crosslinked isomerized type I collagen fragments, independent of the nature of the crosslink (eg, pyrrole, pyridinoline). The assay specificity is guaranteed through the use of 2 monoclonal antibodies, each recognizing linear beta-8AA octapeptides (EKAHD-beta-GGR). The assay, therefore, quantifies all type I collagen degradation fragments that contain the isomerized octapeptide beta-8AA twice (beta-CTx).(Package insert: Elecsys Beta-CrossLaps/serum. Roche Diagnostics; V2.0, 10/2022)
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | OK |
| Gross icterus | Reject |
Method Name
Electrochemiluminescence Immunoassay (ECLIA)
Forms
If not ordering electronically, complete, print, and send a General Request (T239) with the specimen.